Valuation: Incyte Corporation

Market Cap 22.85B 20.41B 19.04B 17.29B 32.55B 2,213B 32.86B 229B 89.41B 1,125B 85.81B 83.95B 3,617B P/E 2026 *
55.6x
P/E 2027 * 15.7x
Enterprise Value 18.58B 16.59B 15.48B 14.06B 26.46B 1,799B 26.71B 186B 72.68B 914B 69.76B 68.24B 2,941B EV / Sales 2026 *
3.13x
EV / Sales 2027 * 2.7x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day-0.61%
1 week-3.75%
Current month-7.09%
1 month-9.36%
3 months-3.85%
6 months+17.58%
Current year+14.15%
1 week 110.08
Extreme 110.08
115.67
1 month 110.08
Extreme 110.08
128.72
Current year 89.25
Extreme 89.25
132.6
1 year 82.82
Extreme 82.815
132.6
3 years 50.27
Extreme 50.27
132.6
5 years 50.27
Extreme 50.27
132.6
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Date Insider Type Main position Quantity % Market Cap. Importance
1/10/26 Tax

EVP, Head of Incyte Intl

-463 0.0002%
30/9/26 Other

Director

0 0% -
30/9/26
FBS Associates LLC
OtherCompany 0 0% -
Change 5-day change 1-year change 3-year change Capi.($)
-0.61%-3.75%+32.06%+96.67% 22.85B
-1.61%+1.72%+38.30%+106.93% 1,043B
-0.76%-0.84%+35.21%+62.70% 618B
+0.39%+4.81%+17.81%+83.77% 481B
-0.29%-0.99%+64.79%+37.06% 351B
-2.03%+1.06%+21.08%+42.16% 338B
-1.92%-0.29%+10.54%+33.20% 269B
-2.36%-1.16%-7.14%+8.68% 244B
-1.37%+0.04%+38.29%+52.33% 220B
+0.17%-0.27%+24.40%+96.82% 182B
Average -1.02%-0.40%+27.53%+62.03% 376.95B
Weighted average by Cap. -1.04%+0.56%+30.47%+69.05%

Financials

2026 *2027 *
Net sales 5.94B 5.3B 4.95B 4.49B 8.46B 575B 8.54B 59.39B 23.23B 292B 22.29B 21.81B 940B 6.26B 5.59B 5.21B 4.73B 8.91B 606B 8.99B 62.56B 24.47B 308B 23.49B 22.98B 990B
Net income 422M 376M 351M 319M 600M 40.83B 606M 4.22B 1.65B 20.75B 1.58B 1.55B 66.73B 1.49B 1.33B 1.24B 1.13B 2.13B 145B 2.15B 14.94B 5.84B 73.53B 5.61B 5.49B 236B
Net Debt -4.28B -3.82B -3.56B -3.24B -6.09B -414B -6.15B -42.76B -16.73B -210B -16.05B -15.7B -677B -5.96B -5.32B -4.97B -4.51B -8.49B -577B -8.57B -59.62B -23.32B -293B -22.38B -21.89B -943B
Projected Income Statement - Annual - Incyte Corporation
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
08/10/26 US$112.75 -0.61% 1,927,095
07/10/26 US$113.44 +0.63% 1,274,765
06/10/26 US$112.73 -1.23% 2,459,572
05/10/26 US$114.13 -1.01% 1,948,758
02/10/26 US$115.30 -1.57% 2,170,193
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - Incyte Corporation
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
112.75USD
Average target price
129.12USD
Spread / Average Target
+14.52%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Incyte Corporation
  1. Stock Market
  2. Stocks
  3. INCY Stock